CRT, CCM and BAT therapies are currently used in our program based on the algorithm described below. Patients with LVEF 25% to 45% may be eligible for CCM, whereas patients with LVEF less than 35% ...

Anumana announced it received FDA breakthrough device designation for its artificial intelligence-guided ECG algorithm for the early identification of cardiac amyloidosis. The breakthrough device ...